Retrospective Comparison of Age-Related Efficacy and Cost of Sugammadex and Neostigmine in Obese Female Patients Undergoing Elective Surgery

Aim: The purpose of the study is to compare the clinical impact and cost of sugammadex and neostigmine in obese, young-elderly patients. Materials and Methods: In this study, the medical and anesthesia records of patients whose operation did not exceed 150 minutes and who used rocuronium as a muscle relaxant were evaluated retrospectively. Patients whose files were examined were divided into 4 groups according to age and drug given; Group YS: 2 mg/kg sugammadex between 20–60 years, Group ES: 2 mg/kg sugammadex between 60-80years, Group YN: 0.04 mg/kg neostigmin + 0.01 mg/kg atropine between 20–60 years, Group EN: 0.04 mg/kg neostigmin + 0.01 mg/kg atropine between 60–80 years. Time of TOF 25, 75, 90 recovery scores were recorded from the anesthesia records of the patients. Results: Regarding the time to reach TOF 25,75,90, it was seen that the patients in Group YS and Group ES reached faster TOF values than Group YN and Group EN ( p<0,05). Compared with neostigmine, patients who were given sugammadex in the same age group were found to have faster recovery time and statistically significant differences (p<0,05). Conclusion: Sugammadex provides rapid and effective reversal of moderate neuromuscular block compared to neostigmine, with a very low incidence of side effects and faster recovery times.